Multiple Sclerosis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis Multiple Sclerosis 2020 – Main Report Dashboard (US)

With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues to evolve. To date, the MS market has accommodated a role for all current therapies due to disease heterogeneity, individualized treatment decisions, and the unique clinical profile that defines each DMT. That said, with each new launch, players in the MS space—both new and established—must assess where their products fit in an increasingly crowded market, especially next-in-class alternatives offering incremental benefits. Meanwhile, competing paradigms of escalation versus early intervention with high-efficacy drugs remain, stoked by the clean clinical profile of Roche/Genentech’s Ocrevus. This national patient-level claims data analysis explores the current DMTs’ positioning, examines line of therapy progression, and assesses persistence and compliance by brand.

Questions Answered

  • What patient shares do key brands garner by line of therapy in newly diagnosed MS patients? What are the recent quarterly trends in prescribing among recently treated and newly diagnosed MS patients?
  • How have new entrants been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of MS patients receive drug therapy within two years of diagnosis? What percentage of patients progress to later lines of therapy within two years of diagnosis?
  • What are the product-level compliance and persistency rates?

Markets covered: United States

Real-world data: Longitudinal patient-level claims data analysis

Key companies: Bayer, Biogen, EMD Serono, Genentech / Roche, Mylan, Novartis, Sanofi Genzyme, Teva

Key drugs covered: Aubagio, Avonex, Betaseron, Copaxone / Glatopa / glatiramer acetate, Extavia, Gilenya, Lemtrada, Mavenclad, Mayzent, Ocrevus, Plegridy, Rebif, Tecfidera, Tysabri

Key analysis provided:

  • Brand/therapy usage across a longitudinal patient sample.
  • Newly diagnosed patient analysis.
  • Treatment initiation and progression.
  • Line of therapy analysis.
  • Combination therapy analysis.
  • Source of business for recently treated patients.
  • Persistency and compliance analysis.
  • Product-level patient flowchart.

Product Description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

The Treatment Algorithms dashboard supplements our claims data analysis report and retains the full set of analyses included in the PowerPoint-based report. The interactive dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.

launch Related Market Assessment Reports